HomeCompareGKAT vs JNJ

GKAT vs JNJ: Dividend Comparison 2026

GKAT yields 0.49% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GKAT wins by $334.00 in total portfolio value
10 years
GKAT
GKAT
● Live price
0.49%
Share price
$40.86
Annual div
$0.20
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$50.35
Full GKAT calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — GKAT vs JNJ

📍 GKAT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGKATJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GKAT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GKAT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GKAT
Annual income on $10K today (after 15% tax)
$41.46/yr
After 10yr DRIP, annual income (after tax)
$42.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $660.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GKAT + JNJ for your $10,000?

GKAT: 50%JNJ: 50%
100% JNJ50/50100% GKAT
Portfolio after 10yr
$20.2K
Annual income
$439.06/yr
Blended yield
2.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GKAT
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GKAT buys
0
JNJ buys
0
No recent congressional trades found for GKAT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGKATJNJ
Forward yield0.49%3.36%
Annual dividend / share$0.20$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.4K$20.0K
Annual income after 10y$50.35$827.78
Total dividends collected$496.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GKAT vs JNJ ($10,000, DRIP)

YearGKAT PortfolioGKAT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,749$48.77$10,676$355.77+$73.00GKAT
2$11,550$49.00$11,407$389.39+$143.00GKAT
3$12,408$49.20$12,198$426.53+$210.00GKAT
4$13,326$49.40$13,056$467.62+$270.00GKAT
5$14,308$49.58$13,987$513.12+$321.00GKAT
6$15,360$49.76$14,998$563.56+$362.00GKAT
7$16,485$49.92$16,098$619.52+$387.00GKAT
8$17,689$50.07$17,295$681.69+$394.00GKAT
9$18,977$50.21$18,599$750.82+$378.00GKAT
10$20,356$50.35$20,022$827.78+$334.00GKAT

GKAT vs JNJ: Complete Analysis 2026

GKATStock

GKAT primarily holds 25 to 40 stocks of any size with strong long-term appreciation potential and limited downside risk. The strategy seeks securities with low valuations combined with growing earnings, cash flow, and/or book value by utilizing five key principles. These include low valuation, discount to fair value, investment flexibility, focus, and a long-term outlook. Investments include common and preferred stocks, rights, warrants, special situations, ADRs, EDRs, and GDRs. At least 40% of the assets are non-US securities. The fund may hold fixed-income securities and ETFs, capped at 30%. It may also fully shift into cash or short-term instruments for liquidity or defensive purposes. Securities are sold when they no longer offer attractive upside or fail to meet valuation and growth criteria. On Aug. 25, 2025, GKAT converted from a mutual fund into an ETF structure, starting with $30.55 million in assets.

Full GKAT Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this GKAT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GKAT vs SCHDGKAT vs JEPIGKAT vs OGKAT vs KOGKAT vs MAINGKAT vs ABBVGKAT vs MRKGKAT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.